For research use only. Not for therapeutic Use.
VU041 is a selective small molecule inhibitor of the P2X7 receptor, a purinergic receptor involved in inflammation and immune responses. By blocking P2X7 receptor activity, VU041 has potential therapeutic applications in diseases characterized by excessive inflammation, such as autoimmune disorders, neuroinflammatory conditions, and chronic pain. It may also have benefits in conditions like cancer and neurodegenerative diseases, where inflammation plays a key role in disease progression. Research is ongoing to fully explore its clinical potential.
| Catalog Number | I017185 |
| CAS Number | 332943-64-3 |
| Molecular Formula | C₁₉H₂₀F₃N₃O |
| Purity | ≥95% |
| Target | Anti-infection |
| IUPAC Name | 1-(3,4-dihydro-2H-quinolin-1-yl)-2-[3-(trifluoromethyl)-4,5,6,7-tetrahydroindazol-1-yl]ethanone |
| InChI | 1S/C19H20F3N3O/c20-19(21,22)18-14-8-2-4-10-16(14)25(23-18)12-17(26)24-11-5-7-13-6-1-3-9-15(13)24/h1,3,6,9H,2,4-5,7-8,10-12H2 |
| InChIKey | DLAGRCZUELSZFG-UHFFFAOYSA-N |
| SMILES | C1CCC2=C(C1)C(=NN2CC(=O)N3CCCC4=CC=CC=C43)C(F)(F)F |
